Clinical trial
A Randomized, Double-blind, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 15 mg of Darifenacin Daily in Patients With Amyotrophic Lateral Sclerosis
NCT06249867 is registered in ClinicalTrials.gov with Oliver Blanchard as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 15 mg of Darifenacin Daily in Patients With Amyotrophic Lateral Sclerosis
- Lead sponsor
- Oliver Blanchard
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 8, 2024
- Completion date
- November 30, 2027
- Enrollment
- 60 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.